DOT1L inhibition exerts the anti-tumor effect by activating interferon signaling in breast cancer cells
These findings suggest that the anti-breast cancer effect of DOT1L inhibition is mediated by multiple mechanisms, including activation of innate immune signaling.
Authors
- Tomohide Tsukahara (ORCID: https://orcid.org/0000-0002-3678-4359)
- Hiroshi Nakase (ORCID: https://orcid.org/0000-0003-2848-6586)
- Masashi Idogawa (ORCID: https://orcid.org/0000-0002-8507-1726)
- Akira Yorozu
- Reo Maruyama (ORCID: https://orcid.org/0000-0001-7166-5964)
- Ayano Yoshido
- Kazuya Ishiguro
- Takeshi Niinuma (ORCID: https://orcid.org/0000-0002-8634-663X)
- Hiroshi Kitajima (ORCID: https://orcid.org/0000-0002-7508-6764)
- Mutsumi Toyota
- Kohei Kumegawa (ORCID: https://orcid.org/0000-0003-3732-2874)
- Masaki MAEZAWA (ORCID: https://orcid.org/0000-0003-2483-4168)
- Hiromu Suzuki (ORCID: https://orcid.org/0000-0001-9635-3238)
- Toshihiko Torigoe (ORCID: https://orcid.org/0000-0002-9463-5917)
- Masahiro Kai
- H. Sasaki (ORCID: https://orcid.org/0009-0009-8777-9478)
- Eiichiro Yamamoto
Institutions
- Sapporo Medical University (JP)
- Japanese Foundation For Cancer Research (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Clinical Epigenetics
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1186/s13148-025-02017-5
- Primary Topic
- Immune Response and Inflammation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministry of Education, Culture, Sports, Science and Technology
- Princess Takamatsu Cancer Research Fund
- Japan Society for the Promotion of Science